An Overview of Cytokine Release Syndrome and Other Side Effects of CAR-T Cell Therapy

Praxis (Bern 1994). 2023;112(3):189-193. doi: 10.1024/1661-8157/a003980.


Oncology has been rapidly evolving over the past decade with tremendous therapeutic development. Engineered cell therapies such as chimeric antigen receptor (CAR)-T cells are increasingly used in daily practice, and provided a paradigm change especially for hematological malignancies. Their development is a scientific and technological achievement, but their toxicities can be life-threatening. As their utilization expands, better understanding of pathophysiology leads to better management. In this article we present a general overview of cell-therapy toxicities and their management.

Keywords: Cytokine release syndrome; Immuneffektorzell-assoziiertes Neurotoxizitätssyndrom; Syndrome de libération cytokinique; Zelltherapien; Zytokinfreisetzungssyndrom; cell therapies; chimeric antigen receptor; chimärer Antigenrezeptor; immune effector cell-associated neurotoxicity syndrome; récepteur d’antigène chimérique; syndrome de neurotoxicité associé aux cellules effectrices du système immunitaire; thérapies cellulaires.

MeSH terms

  • Cell- and Tissue-Based Therapy
  • Cytokine Release Syndrome / etiology
  • Cytokine Release Syndrome / therapy
  • Hematologic Neoplasms* / therapy
  • Humans
  • Receptors, Chimeric Antigen* / therapeutic use


  • Receptors, Chimeric Antigen